Novel Approaches for Improving Vascular Function in Veterans With HFpEF

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-19

Study Completion Date

2030-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure

NCT01474486

Congestive Heart Failure Ischemic Cardiomyopathy

COMPLETED NA

Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)

NCT02713126

Heart Failure

COMPLETED PHASE2

The Re-Prosper HF Study

NCT04551222

Heart Failure

COMPLETED PHASE2/PHASE3

Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

NCT00585546

Heart Failure Dilated Cardiomyopathy

TERMINATED PHASE1

Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure

NCT01661634

Acute Decompensated Heart Failure

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The hospital admission rate for Veterans with heart failure with a preserved ejection fraction (HFpEF) continues to rise within the VA Health Care System, making HF the number one reason for hospital discharge Additionally, readmission rates of Veterans with HF tend to be higher than the national average, emphasizing the shortcomings of current therapeutic strategies Indeed, while optimized pharmacotherapy has led to a declining mortality in heart failure with reduced ejection fraction (HFrEF) patients, similar therapies in patients with HFpEF have been unsuccessful in altering the natural history of the disease Clearly, alternative therapeutic approaches are needed to improve outcomes in this ever-growing Veteran patient group.

The clinical presentation of HFpEF continues to be defined by dyspnea upon exertion and severe exercise intolerance symptoms that are unlikely due to a simple deficit in cardiac mechanics Indeed, the contribution of vascular dysfunction to exercise intolerance in patients with HFpEF has recently been identified highlighting the importance of disease-related changes in the peripheral circulation to HFpEG pathophysiology. While the mechanisms responsible for vascular dysfunction in HFpEF have not been established, there is an emerging concept that chronic inflammation and the associated production of reactive oxygen species (ROS), stemming from HFpEF-associated comorbidities and inactivity, plays a crucial role. The proposed work seeks to address this important knowledge gap by examining the mechanisms linking inflammation, vascular health, and exercise tolerance in Veterans with HFpEF, and identifying which aspects of this cascade could be targeted to improve outcomes in this patient group.

In HFpEF, the peripheral vasculature represents an area that is particularly vulnerable to the harmful effects of circulating ROS due to the interaction with nitric oxide (NO). Indeed, following formation and release from the endothelium, the fate of NO is dictated to a large degree by the presence of ROS that catalyze the formation of peroxynitrite (ONOO-), thereby decreasing NO bioavailability. This deleterious effect on NO formation is amplified by ONOO--mediated oxidation of tetrahydrobiopterin (BH4), effectively "uncoupling" endothelial nitric oxide synthase (eNOS) and thus further diminishing NO production. Bioavailability of NO may also be diminished through reductions in precursor (L-Arginine/L-Citrulline) availability, such that a "substrate limitation" may also be present in patients with HFpEF.

While the potential of increased NO bioavailability to improve outcomes in patients with HFpEF has been increasingly recognized, results from clinical trials utilizing NO donors have been largely negative, suggesting a more comprehensive approach may be needed. Thus, the overall goal of the project is to evaluate the mechanisms responsible for vascular dysfunction and exercise intolerance in Veterans with HFpEF, which will be accomplished through selective pharmacologic targeting of distinct pathways known to regulate vascular NO signaling. The investigators have identified three discreet points in the cascade from inflammation to vascular dysfunction that may represent therapeutic targets for improving exercise tolerance in patients with HFpEF, and thus propose a series of integrative aims that will combine novel methodology with targeted pharmacologic interventions to selectively determine the importance of NO substrate, enzymatic cofactor bioavailability, and statin-induced mitigation of inflammation and ROS to disease-related changes in inflammation and NO signaling in HFpEF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure With Preserved Ejection Fraction Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

A block randomization method will be used to randomize participants into equal groups and will be handled by investigational pharmacist.

Intervention Type DRUG

Atorvastatin-matched Placebo

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older and able to give written informed consent.
* New York Heart Association (NYHA) functional class I, II, or III.
* Left Ventricular Ejection Fraction (LVEF) \> 50%.
* Plasma Brain Natriuretic Peptide (BNP) equal to or greater than 150 pg/mL or NT-proBNP equal to or greater than 600 pg/mL at Visit 1, or a BNP equal to or great than 100 pg/mL (or NT-proBNP equal to or greater than 400 pg/mL) and a hospitalization for heart failure within the last 12 months.

Exclusion Criteria

* History of hypersensitivity or allergy to any lipophilic statin.
* Prior EF \<50%.
* NYHA Class IV.
* Patients with HFpEF secondary to significant uncorrected primary valvular disease.
* Active liver disease or unexplained persistent elevations in serum transaminase.
* Women who are pregnant or may become pregnant.
* Patients currently treated with antioxidants, nitrates, PDE-5 inhibitors, or statins.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No